You have accessJournal of UrologyProstate Cancer: Localized: Active Surveillance II1 Apr 2017MP43-19 ACTIVE SURVEILLANCE FOR FAVORABLE-RISK PROSTATE CANCER IN AFRICAN CARIBBEAN MEN: RESULTS OF A PROSPECTIVE STUDY Matthias Meunier, Rémi Eyraud, Cédric Sénéchal, Gilles Gourtaud, Virginie Roux, Cécilia Lanchon, Laurent Brureau, and Pascal Blanchet Matthias MeunierMatthias Meunier More articles by this author , Rémi EyraudRémi Eyraud More articles by this author , Cédric SénéchalCédric Sénéchal More articles by this author , Gilles GourtaudGilles Gourtaud More articles by this author , Virginie RouxVirginie Roux More articles by this author , Cécilia LanchonCécilia Lanchon More articles by this author , Laurent BrureauLaurent Brureau More articles by this author , and Pascal BlanchetPascal Blanchet More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.1329AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Active surveillance (AS) is a treatment option for favorable-risk prostate cancers (PCa). However, data concerning populations of African descent is missing. The objective of this study was to evaluate the safety and benefit of AS in an African Caribbean cohort with favorable-risk PCa. METHODS Between 2005 and 2016, a monocentric prospective cohort study was conducted in Guadeloupe (French West Indies), including patients with low-risk PCa (prostate-specific antigen [PSA] =10 ng/ml; Gleason =6) or favorable intermediate-risk PCa (PSA, 10-20 ng/ml; Gleason =7 (3+4); life expectancy <10 years) in AS. Treatment was recommended in case of histological progression, increase in tumor volume, PSA doubling time <36 months or patient’s wish. Outcomes were overall survival, disease-specific survival and duration of AS, calculated with the Kaplan-Meier method. Multivariate analysis was performed using the Cox proportional hazards model to identify predictors of AS termination. RESULTS A total of 234 patients (median age 64 yr) were enrolled in the study. Median follow-up was 4 years (interquartile range: 2.3-5.5 yr). Overall survival at 30 months, 5 and 10 years was 99.5%, 98.5%, 90.7% respectively. Disease-specific survival at 30 months, 5 and 10 years was 100%. At 30 months, 5 and 10 years, 72.7%, 52.6%, 40.4% of patients respectively remained untreated and under AS. Age (hazard ratio [HR], 0.96 per additional year; 95% confidence interval [CI], 0.93-0.99) and PSA density (HR, 1.52 per additional 0.1; 95% CI, 1.20-1.89) were found to be independent predictors of AS termination. CONCLUSIONS AS seems to be safe and beneficial for African Caribbean men with favorable-risk PCa. The high rate of patients leaving AS may reflect a greater proportion of aggressive cancers in this population. PSA density could help to better select these patients. Longer follow-up is needed to confirm these results. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e561-e562 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Matthias Meunier More articles by this author Rémi Eyraud More articles by this author Cédric Sénéchal More articles by this author Gilles Gourtaud More articles by this author Virginie Roux More articles by this author Cécilia Lanchon More articles by this author Laurent Brureau More articles by this author Pascal Blanchet More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...